PGDx, the defendant in the liquid biopsy IP case, has alleged that Guardant's CEO should have been named as an inventor on patents but was purposefully left off.
The company's cofounders will pay $500,000 each to settle allegations by the US Department of Justice that they submitted false claims to Medicare.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.
CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
Roche alleged that lower-priced test strips intended for sale via mail order were redirected for sale at higher prices through retail pharmacies.
Magnolia has amended a complaint filed in a US District Court to allege that Kurin infringes four Magnolia patents.
DOJ alleges that Arriva offered free upgrades of medically unnecessary glucometers to Medicare beneficiaries, and then billed Medicare for the equipment.
The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
Mayo's diagnostic tests do not infringe upon Athena Diagnostics' patent because they use standard methods and involve "natural law," the court ruled.